Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Puoliväli J[au]:

Search results

Items: 45

1.

Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice.

Datson NA, Bijl S, Janson A, Testerink J, van den Eijnde R, Weij R, Puoliväli J, Lehtimäki K, Bragge T, Ahtoniemi T, van Deutekom JC.

Nucleic Acid Ther. 2020 Feb;30(1):50-65. doi: 10.1089/nat.2019.0824. Epub 2019 Dec 10.

PMID:
31821107
2.

Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide.

Kourkouta E, Weij R, González-Barriga A, Mulder M, Verheul R, Bosgra S, Groenendaal B, Puoliväli J, Toivanen J, van Deutekom JCT, Datson NA.

Mol Ther Nucleic Acids. 2019 Sep 6;17:601-614. doi: 10.1016/j.omtn.2019.07.004. Epub 2019 Jul 19.

3.

Impaired Performance of the Q175 Mouse Model of Huntington's Disease in the Touch Screen Paired Associates Learning Task.

Piiponniemi TO, Parkkari T, Heikkinen T, Puoliväli J, Park LC, Cachope R, Kopanitsa MV.

Front Behav Neurosci. 2018 Oct 2;12:226. doi: 10.3389/fnbeh.2018.00226. eCollection 2018.

4.

Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Collier AF, Gumerson J, Lehtimäki K, Puoliväli J, Jones JW, Kane MA, Manne S, O'Neill A, Windish HP, Ahtoniemi T, Williams BA, Albrecht DE, Bloch RJ.

J Pharmacol Exp Ther. 2018 Mar;364(3):409-419. doi: 10.1124/jpet.117.244244. Epub 2017 Dec 28.

5.

Acquisition and reversal of visual discrimination learning in APPSwDI/Nos2-/- (CVN) mice.

Piiponniemi TO, Bragge T, Vauhkonen EE, Vartiainen P, Puoliväli JT, Sweeney PJ, Kopanitsa MV.

Neurosci Lett. 2017 May 22;650:126-133. doi: 10.1016/j.neulet.2017.04.049. Epub 2017 Apr 26.

6.

Hip region muscular dystrophy and emergence of motor deficits in dysferlin-deficient Bla/J mice.

Nagy N, Nonneman RJ, Llanga T, Dial CF, Riddick NV, Hampton T, Moy SS, Lehtimäki KK, Ahtoniemi T, Puoliväli J, Windish H, Albrecht D, Richard I, Hirsch ML.

Physiol Rep. 2017 Mar;5(6). pii: e13173. doi: 10.14814/phy2.13173.

7.

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.

Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, Tombaugh G, Gelman S, Bradaia A, Steidl E, Gleyzes M, Heikkinen T, Lehtimäki K, Puoliväli J, Kontkanen O, Javier RM, Neagoe I, Deisemann H, Winkler D, Ebneth A, Khetarpal V, Toledo-Sherman L, Dominguez C, Park LC, Munoz-Sanjuan I.

Exp Neurol. 2016 Aug;282:99-118. doi: 10.1016/j.expneurol.2016.05.005. Epub 2016 May 6.

PMID:
27163548
8.

Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound.

Khatoon S, Chalbot S, Bolognin S, Puoliväli J, Iqbal K.

J Alzheimers Dis. 2015;47(3):557-64. doi: 10.3233/JAD-142799.

PMID:
26401692
9.

Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats.

Levijoki J, Kivikko M, Pollesello P, Sallinen J, Hyttilä-Hopponen M, Kuoppamäki M, Haasio K, Gröhn O, Miettinen R, Puoliväli J, Tähtivaara L, Yrjänheikki J, Haapalinna A.

Eur J Pharmacol. 2015 Mar 5;750:132-40. doi: 10.1016/j.ejphar.2015.01.037. Epub 2015 Jan 29.

10.

Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease.

Ragauskas S, Leinonen H, Puranen J, Rönkkö S, Nymark S, Gurevicius K, Lipponen A, Kontkanen O, Puoliväli J, Tanila H, Kalesnykas G.

PLoS One. 2014 Dec 3;9(12):e113317. doi: 10.1371/journal.pone.0113317. eCollection 2014.

11.

mNos2 deletion and human NOS2 replacement in Alzheimer disease models.

Colton CA, Wilson JG, Everhart A, Wilcock DM, Puoliväli J, Heikkinen T, Oksman J, Jääskeläinen O, Lehtimäki K, Laitinen T, Vartiainen N, Vitek MP.

J Neuropathol Exp Neurol. 2014 Aug;73(8):752-69. doi: 10.1097/NEN.0000000000000094.

12.

Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.

Bolognin S, Buffelli M, Puoliväli J, Iqbal K.

Neurobiol Aging. 2014 Sep;35(9):2134-46. doi: 10.1016/j.neurobiolaging.2014.02.017. Epub 2014 Mar 2.

PMID:
24702821
13.

Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.

Heikkinen T, Lehtimäki K, Vartiainen N, Puoliväli J, Hendricks SJ, Glaser JR, Bradaia A, Wadel K, Touller C, Kontkanen O, Yrjänheikki JM, Buisson B, Howland D, Beaumont V, Munoz-Sanjuan I, Park LC.

PLoS One. 2012;7(12):e50717. doi: 10.1371/journal.pone.0050717. Epub 2012 Dec 20.

14.

The radical scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) decreases mortality, enhances cognitive functions in water maze and reduces amyloid plaque burden in hAβPP transgenic mice.

Puoliväli J, Nurmi A, Miettinen TK, Soleti A, Riccardino F, Kalesnykas G, Heikkinen T, Vartiainen N, Pussinen R, Tähtivaara L, Lehtimäki K, Yrjänheikki J, Canistro D, Sapone A, Spisni E, Paolini M.

J Alzheimers Dis. 2011;27(3):499-510. doi: 10.3233/JAD-2011-110881.

PMID:
21821875
15.

Cerebral blood volume alterations in the perilesional areas in the rat brain after traumatic brain injury--comparison with behavioral outcome.

Immonen R, Heikkinen T, Tähtivaara L, Nurmi A, Stenius TK, Puoliväli J, Tuinstra T, Phinney AL, Van Vliet B, Yrjänheikki J, Gröhn O.

J Cereb Blood Flow Metab. 2010 Jul;30(7):1318-28. doi: 10.1038/jcbfm.2010.15. Epub 2010 Feb 10.

16.

Neuroprotective properties of the non-peptidyl radical scavenger IAC in rats following transient focal cerebral ischemia.

Nurmi A, Miettinen TK, Puoliväli J, Pussinen R, Soleti A, Bagate K, Riccardino F, Grundy RI, Yrjänheikki J, Canistro D, Paolini M.

Brain Res. 2008 May 1;1207:174-81. doi: 10.1016/j.brainres.2008.02.027. Epub 2008 Feb 21.

PMID:
18374313
17.

Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.

Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe KH, Muchowski PJ, Mucke L.

J Biol Chem. 2007 Aug 17;282(33):23818-28. Epub 2007 Jun 4.

18.

beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits.

Malm T, Ort M, Tähtivaara L, Jukarainen N, Goldsteins G, Puoliväli J, Nurmi A, Pussinen R, Ahtoniemi T, Miettinen TK, Kanninen K, Leskinen S, Vartiainen N, Yrjänheikki J, Laatikainen R, Harris-White ME, Koistinaho M, Frautschy SA, Bures J, Koistinaho J.

Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8852-7. Epub 2006 May 24.

19.

Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice.

Esposito L, Raber J, Kekonius L, Yan F, Yu GQ, Bien-Ly N, Puoliväli J, Scearce-Levie K, Masliah E, Mucke L.

J Neurosci. 2006 May 10;26(19):5167-79.

20.

Effects of estradiol on spatial learning, hippocampal cytochrome P450 19, and estrogen alpha and beta mRNA levels in ovariectomized female mice.

Iivonen S, Heikkinen T, Puoliväli J, Helisalmi S, Hiltunen M, Soininen H, Tanila H.

Neuroscience. 2006;137(4):1143-52. Epub 2005 Dec 2.

PMID:
16326017
21.

Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.

Yavich L, Oksman M, Tanila H, Kerokoski P, Hiltunen M, van Groen T, Puoliväli J, Männistö PT, García-Horsman A, MacDonald E, Beyreuther K, Hartmann T, Jäkälä P.

Neurobiol Dis. 2005 Nov;20(2):303-13.

PMID:
16242637
22.

Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease.

Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L.

J Neurosci. 2005 Oct 19;25(42):9694-703.

23.

Reelin-immunoreactivity in the hippocampal formation of 9-month-old wildtype mouse: effects of APP/PS1 genotype and ovariectomy.

Miettinen R, Riedel A, Kalesnykas G, Kettunen HP, Puoliväli J, Soininen H, Arendt T.

J Chem Neuroanat. 2005 Oct;30(2-3):105-18.

PMID:
16081247
24.

The effect of aging on the subcellular distribution of estrogen receptor-alpha in the cholinergic neurons of transgenic and wild-type mice.

Kalesnykas G, Roschier U, Puoliväli J, Wang J, Miettinen R.

Eur J Neurosci. 2005 Mar;21(5):1437-42.

PMID:
15813954
25.

Effects of long-term ovariectomy and estrogen treatment on maze learning in aged mice.

Heikkinen T, Puoliväli J, Tanila H.

Exp Gerontol. 2004 Sep;39(9):1277-83.

PMID:
15489050
26.

Cholinergic neurons in the basal forebrain of aged female mice.

Kalesnykas G, Puoliväli J, Sirviö J, Miettinen R.

Brain Res. 2004 Oct 1;1022(1-2):148-56.

PMID:
15353224
27.

Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation.

Heikkinen T, Kalesnykas G, Rissanen A, Tapiola T, Iivonen S, Wang J, Chaudhuri J, Tanila H, Miettinen R, Puoliväli J.

Exp Neurol. 2004 May;187(1):105-17.

PMID:
15081593
28.

Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice.

Wang J, Tanila H, Puoliväli J, Kadish I, van Groen T.

Neurobiol Dis. 2003 Dec;14(3):318-27. Erratum in: Neurobiol Dis. 2004 Jun;16(1):following 289.

PMID:
14678749
29.

Hypothermia in mice tested in Morris water maze.

Iivonen H, Nurminen L, Harri M, Tanila H, Puoliväli J.

Behav Brain Res. 2003 May 15;141(2):207-13.

PMID:
12742257
30.

Alpha 2C-adrenoceptor mediated regulation of cortical EEG arousal.

Puoliväli J, Björklund M, Holmberg M, Ihalainen JA, Scheinin M, Tanila H.

Neuropharmacology. 2002 Dec;43(8):1305-12.

PMID:
12527480
31.

Estrogen treatment alleviates NMDA-antagonist induced hippocampal LTP blockade and cognitive deficits in ovariectomized mice.

Gureviciene I, Puoliväli J, Pussinen R, Wang J, Tanila H, Ylinen A.

Neurobiol Learn Mem. 2003 Jan;79(1):72-80.

PMID:
12482681
32.

Effects of fimbria-fornix lesion and amyloid pathology on spatial learning and memory in transgenic APP+PS1 mice.

Liu L, Ikonen S, Heikkinen T, Heikkilä M, Puoliväli J, van Groen T, Tanila H.

Behav Brain Res. 2002 Aug 21;134(1-2):433-45.

PMID:
12191831
33.

Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice.

Marutle A, Unger C, Hellström-Lindahl E, Wang J, Puoliväli J, Tanila H, Nordberg A, Zhang X.

Neurosci Lett. 2002 Aug 16;328(3):269-72.

PMID:
12147323
34.

Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease.

Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puoliväli J, Salminen A, Helisalmi S, Soininen H.

Neuroscience. 2002;113(2):301-10.

PMID:
12127087
35.

Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice.

Puoliväli J, Wang J, Heikkinen T, Heikkilä M, Tapiola T, van Groen T, Tanila H.

Neurobiol Dis. 2002 Apr;9(3):339-47.

PMID:
11950278
36.

Effects of ovariectomy and estrogen treatment on learning and hippocampal neurotransmitters in mice.

Heikkinen T, Puoliväli J, Liu L, Rissanen A, Tanila H.

Horm Behav. 2002 Feb;41(1):22-32.

PMID:
11863380
37.

Apolipoprotein E-deficient mice are not more susceptible to the biochemical and memory deficits induced by nucleus basalis lesion.

Puoliväli J, Miettinen R, Pradier L, Riekkinen P Jr.

Neuroscience. 2000;96(2):291-7.

PMID:
10683569
38.
39.

Estrogen and NMDA receptor antagonism: effects upon reference and working memory.

Wilson IA, Puoliväli J, Heikkinen T, Riekkinen P Jr.

Eur J Pharmacol. 1999 Sep 24;381(2-3):93-9.

PMID:
10554875
40.

Moderate cortical EEG changes in apolipoprotein E-deficient mice during ageing and scopolamine treatment but not after nucleus basalis lesion.

Puoliväli J, Pradier L, Riekkinen P Jr.

Psychopharmacology (Berl). 1999 Aug;145(4):386-92.

PMID:
10460315
41.

In mice tonic estrogen replacement therapy improves non-spatial and spatial memory in a water maze task.

Rissanen A, Puoliväli J, van Groen T, Riekkinen P Jr.

Neuroreport. 1999 Apr 26;10(6):1369-72.

PMID:
10363955
42.

Oxotremorine suppresses thalamocortical oscillations via thalamic muscarinic acetylcholine receptors.

Puoliväli J, Jäkälä P, Koivisto E, Riekkinen P Jr.

Psychopharmacology (Berl). 1998 Dec;140(3):285-92.

PMID:
9877008
43.

Alpha2C-adrenoceptor-overexpressing mice are impaired in executing nonspatial and spatial escape strategies.

Björklund M, Sirviö J, Puoliväli J, Sallinen J, Jäkälä P, Scheinin M, Kobilka BK, Riekkinen P Jr.

Mol Pharmacol. 1998 Sep;54(3):569-76.

PMID:
9730916
44.

Muscarinic M1 and M2 receptor subtype selective drugs modulate neocortical EEG via thalamus.

Puoliväli J, Jäkälä P, Koivisto E, Riekkinen P Jr.

Neuroreport. 1998 Jun 1;9(8):1685-9.

PMID:
9665583
45.

Activation of acetylcholine receptors and 5-HT2 receptors have additive effects in the suppression of neocortical high-voltage spindles in aged rats.

Jäkälä P, Puolivali J, Björklund M, Koivisto E, Riekkinen P Jr.

Psychopharmacology (Berl). 1997 Aug;132(3):270-80.

PMID:
9292627

Supplemental Content

Loading ...
Support Center